327 related articles for article (PubMed ID: 25172669)
1. On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation.
Skeppholm M; Hjemdahl P; Antovic JP; Muhrbeck J; Eintrei J; Rönquist-Nii Y; Pohanka A; Beck O; Malmström RE
Thromb Res; 2014 Oct; 134(4):783-9. PubMed ID: 25172669
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma.
Antovic JP; Skeppholm M; Eintrei J; Boija EE; Söderblom L; Norberg EM; Onelöv L; Rönquist-Nii Y; Pohanka A; Beck O; Hjemdahl P; Malmström RE
Eur J Clin Pharmacol; 2013 Nov; 69(11):1875-81. PubMed ID: 23784008
[TBL] [Abstract][Full Text] [Related]
3. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays.
Douxfils J; Lessire S; Dincq AS; Hjemdahl P; Rönquist-Nii Y; Pohanka A; Gourdin M; Chatelain B; Dogné JM; Mullier F
Thromb Haemost; 2015 Apr; 113(4):862-9. PubMed ID: 25519251
[TBL] [Abstract][Full Text] [Related]
4. Measurement of dabigatran plasma concentrations by calibrated thrombin clotting time in comparison to LC-MS/MS in human volunteers on dialysis.
Schmohl M; Gansser D; Moschetti V; Stangier J
Thromb Res; 2015 Mar; 135(3):532-6. PubMed ID: 25600440
[TBL] [Abstract][Full Text] [Related]
5. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate.
Douxfils J; Dogné JM; Mullier F; Chatelain B; Rönquist-Nii Y; Malmström RE; Hjemdahl P
Thromb Haemost; 2013 Sep; 110(3):543-9. PubMed ID: 23783171
[TBL] [Abstract][Full Text] [Related]
6. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples.
Hapgood G; Butler J; Malan E; Chunilal S; Tran H
Thromb Haemost; 2013 Aug; 110(2):308-15. PubMed ID: 23783268
[TBL] [Abstract][Full Text] [Related]
7. CHA2DS2-VASc and HAS-BLED scores and activated partial thromboplastin time for prediction of high plasma concentration of dabigatran at trough.
Owada S; Tomita H; Kinjo T; Ishida Y; Itoh T; Sasaki K; Horiuchi D; Kimura M; Sasaki S; Okumura K
Thromb Res; 2015 Jan; 135(1):62-7. PubMed ID: 25466835
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation.
Skeppholm M; Al-Aieshy F; Berndtsson M; Al-Khalili F; Rönquist-Nii Y; Söderblom L; Östlund AY; Pohanka A; Antovic J; Malmström RE
Thromb Res; 2015 Jul; 136(1):148-53. PubMed ID: 25981142
[TBL] [Abstract][Full Text] [Related]
9. Dabigatran Concentration: Variability and Potential Bleeding Prediction In "Real-Life" Patients With Atrial Fibrillation.
Šinigoj P; Malmström RE; Vene N; Rönquist-Nii Y; Božič-Mijovski M; Pohanka A; Antovic JP; Mavri A
Basic Clin Pharmacol Toxicol; 2015 Nov; 117(5):323-9. PubMed ID: 25981948
[TBL] [Abstract][Full Text] [Related]
10. The anticoagulant effect of therapeutic levels of dabigatran in atrial fibrillation evaluated by thrombelastography (TEG
Solbeck S; Jensen AS; Maschmann C; Stensballe J; Ostrowski SR; Johansson PI
Scand J Clin Lab Invest; 2018; 78(1-2):25-30. PubMed ID: 29304563
[TBL] [Abstract][Full Text] [Related]
11. Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay.
Gosselin RC; Dwyre DM; Dager WE
Ann Pharmacother; 2013 Dec; 47(12):1635-40. PubMed ID: 24259624
[TBL] [Abstract][Full Text] [Related]
12. Relation between dabigatran concentration, as assessed using the direct thrombin inhibitor assay, and activated clotting time/activated partial thromboplastin time in patients with atrial fibrillation.
Okubo K; Kuwahara T; Takagi K; Takigawa M; Nakajima J; Watari Y; Nakashima E; Yamao K; Fujino T; Tsutsui H; Takahashi A
Am J Cardiol; 2015 Jun; 115(12):1696-9. PubMed ID: 25918026
[TBL] [Abstract][Full Text] [Related]
13. Whole blood coagulation assays ROTEM and T-TAS to monitor dabigatran treatment.
Taune V; Wallén H; Ågren A; Gryfelt G; Sjövik C; Wintler AM; Malmström RE; Wikman A; Skeppholm M
Thromb Res; 2017 May; 153():76-82. PubMed ID: 28347811
[TBL] [Abstract][Full Text] [Related]
14. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
[TBL] [Abstract][Full Text] [Related]
15. [Monitoring of Oral Thrombin Inhibitor].
Matsuno K; Usami T; Hatuse M; Shimizu C
Rinsho Byori; 2014 Oct; 62(10):958-64. PubMed ID: 27526541
[TBL] [Abstract][Full Text] [Related]
16. [Hemodialysis to remove anticoagulant dabigatran during emergencies].
Carrizo A; Campbell S
Medicina (B Aires); 2014; 74(2):121-3. PubMed ID: 24736256
[TBL] [Abstract][Full Text] [Related]
17. From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples.
Helin TA; Lemponen M; Hjemdahl P; Rönquist-Nii Y; Lassila R; Joutsi-Korhonen L
Thromb Res; 2015 Jul; 136(1):154-60. PubMed ID: 25981140
[TBL] [Abstract][Full Text] [Related]
18. Real life dabigatran and metabolite concentrations, focused on inter-patient variability and assay differences in patients with atrial fibrillation.
Boonen K; Schmitz E; Rozestraten F; van den Heuvel D; Brunsveld L; van der Voort P; van de Kerkhof D
Clin Chem Lab Med; 2017 Oct; 55(12):2002-2009. PubMed ID: 28328523
[TBL] [Abstract][Full Text] [Related]
19. The effect of dabigatran on thrombin generation and coagulation assays in rabbit and human plasma.
Zhang C; Zhang P; Li H; Han L; Zhang L; Zhang L; Yang X
Thromb Res; 2018 May; 165():38-43. PubMed ID: 29558660
[TBL] [Abstract][Full Text] [Related]
20. Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assays.
van Ryn J; Grottke O; Spronk H
Clin Lab Med; 2014 Sep; 34(3):479-501. PubMed ID: 25168938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
